Salute e Benessere

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge…

Saint Herblain (France) and Schlieren (Zurich) ,November 13, 2024 –Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, andLimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2b controlled human infection model (CHIM) study of Shigella4V2 (S4V2), the world's most clinically advanced tetravalent bioconjugate...
Nasdaq GlobeNewswire
13/11/2024

Crossject's ZENEO® Auto-Injector's usability further demonstrated in extreme…

Crossject successfully completes a new U.S. summative human factors study to assess the usability of ZENEO® Midazolam, soon to be commercialized globally as ZEPIZURE®, under simulated chemical attack conditions. Rigorous HAZMAT (Hazardous Materials) dry-run involved 75 participants, who deployed 375 ZENEO® Midazolam auto-injectors in challenging conditions, including while wearing protective suits, without any handling problem.Study underscores ZENEO® Midazolam's usability in...
Nasdaq GlobeNewswire
13/11/2024

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 13 November 2024— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and...
Nasdaq GlobeNewswire
13/11/2024

The board of "Maxima grupė" has had its term extended for another term.

On November 13, 2024, the sole shareholder of MAXIMA GRUPĖ, UAB, UAB "Vilniaus prekyba", made a decision to extend the term of office of the current board for a new four-year term. The board of MAXIMA GRUPĖ, UAB consists of: Manfredas Dargužis, Jolanta Bivainytė, Petar Petrov Pavlov, Lauryna Šaltinė, Agnė Voverė, Arūnas Zimnickas, and Karolina Zygmantaitė. Additional InformationMAXIMA GRUPĖ, UAB manages the retail chains "Maxima" (in the Baltic States), "Stokrotka"…
Nasdaq GlobeNewswire
13/11/2024

Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a…

177 Lu-PSMA-I&T (INN: lutetium ( 177 Lu) zadavotide guraxetan) versus hormone therapy in patients with metastatic castration-resistant prostate cancer.The ECLIPSE trial demonstrated a statistically significant and clinically meaningful improvement in the median radiographic progression-free survival (rPFS) of patients with prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer (mCRPC) after treatment with up to 6 doses of 200 mCi (7.4 GBq) of...
Nasdaq GlobeNewswire
13/11/2024

Genomics Market to Hit USD 66.85 Billion by 2029 with 9.4% CAGR |…

Browse in-depth TOC on "Genomics Market"671 - Tables68 - Figures562 - Pages Browse in-depth TOC on "Genomics Market" 671 - Tables 68 - Figures 562 - Pages Based on offerings,the genomics market is divided into product and service segments. The product segment accounted for the largest share of the genomics market in 2023. This dominance is primarily attributable to the reagents, kits, and other consumables used in sequencing, PCR, and microarray technologies, which represent…
PR Newswire
13/11/2024

DEBx Medical Secures Expanded Investment from TVM Capital Healthcare

Propelling the Next Phase of Innovation in Chronic Wound Management DEBx Medical is poised for accelerated growth in chronic wound solutions, bolstered by the second round of investment by TVM Capital Healthcare. AMSTERDAM and DUBAI, United Arab Emirates, Nov.13, 2024(GLOBE NEWSWIRE) -- DEBx Medical, an Amsterdam-based pioneering innovator in the field of advanced wound care, announces the successful completion of its second capital investment round led byTVM Capital Healthcare...
Nasdaq GlobeNewswire
13/11/2024

ZINZINO AB (PUBL): Zinzino announces Canary Islands as next step in its global…

Market analysis shows that direct selling is a natural way of earning for people seeking an extra income. Digital commerce is growing rapidly and social selling combined with Zinzino's digital toolbox creates favorable conditions for distributors to reach new customers in the Canary Islands. Market analysis shows that direct selling is a natural way of earning for people seeking an extra income. Digital commerce is growing rapidly and social selling combined with Zinzino's digital toolbox...
PR Newswire
13/11/2024

New Evidence-Based Information from NCCN Offers Tangible and Moral Support for…

"For every patient with cancer who is smoking at diagnosis or anytime during their cancer journey, quitting is absolutely possible. Quitting earlier is better, but any time helps," said Peter G. Shields, MD, of The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute. Dr. Shields serves as Chair of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Panel for Smoking Cessation, which develops evidence-based, expert…
PR Newswire
13/11/2024

Evaxion receives and appeals delisting determination from Nasdaq, remains…

As anticipated, Evaxion has received a delisting determinationThe determination has been appealed by Evaxion requesting a hearing on the matter and seeking another 180-day extension to comply with Nasdaq's equity requirementEvaxion remain committed to ensuring compliance and maintain our Nasdaq listingCOPENHAGEN, Denmark, November 13, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...
Nasdaq GlobeNewswire
13/11/2024

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody®…

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on biologic-naïve patients and including evaluation of radiographic progression (IZAR-1), and the other focusing on TNF-IR patients while being the first trial to include risankizumab as an active reference arm (IZAR-2)Program will evaluate sonelokimab for a total of 52 weeks, across IZAR-1...
Nasdaq GlobeNewswire
13/11/2024

Continuity Biosciences Launches to Enable Breakthrough Therapies with Innovative…

"We are thrilled to have licensed several technology platforms from Houston Methodist Hospital and to introduce Continuity Biosciences to the biotechnology and investment communities," said Ramakrishna Venugopalan, Co-Founder & CEO. "There is immense potential at the intersection of biopharmaceuticals and medical technologies, especially in creating combination products that enhance novel therapies. We plan to expand our technology portfolio to provide our partners with…
PR Newswire
13/11/2024

NaoTrac Robot Pioneers Robotic Neurosurgery in Bolivia with Successful Brain…

Nelson Farfan Espada, Brain Navi's Managing Director for Latin America collaborated closely with the distributor ICERLAB S.R.L. and Hospital Arcoiris to make this groundbreaking initiative a reality. Reflecting on the journey, he shared, "After a challenging yet deeply rewarding process, I believe this program will truly benefit the people of Bolivia. By embracing the latest advancements in precision medicine, we are giving Bolivians access to world-class medical care and the opportunity…
PR Newswire
13/11/2024

Change in management board

On 13 November 2024, Malene Lunddal Hansen was elected to the management board in Coloplast Finance B.V. replacing Hea Vinskov. Malene Lunddal Hansen is Senior Director for Tax & Compliance in the Coloplast group. The management board in Coloplast Finance B.V. hereafter consists of: Henrik Deneke, Anton Mikkelsen and Malene Lunddal Hansen. Attachment 07_2024_Change_in_management_board
Nasdaq GlobeNewswire
13/11/2024

AC Immune to Present at the Jefferies 2024 London Healthcare Conference

AC Immune to Present at the Jefferies 2024 London Healthcare ConferenceLausanne, Switzerland, November 13, 2024– AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 London Healthcare Conference, taking place in-person in London on November 19-21, 2024.The fireside chat...
Nasdaq GlobeNewswire
13/11/2024

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments.Per November 11, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,180,630 shares, corresponding to 4.94% (previously 5.02%) of the total share capital attached to shares. The combined total of share...
Nasdaq GlobeNewswire
13/11/2024

BioNTech to Acquire Biotheus to Boost Oncology Strategy

Acquisition to support the global execution of BioNTech's oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to replace current checkpoint inhibitor standard of care treatments for solid tumorsWith the acquisition of Biotheus, BioNTech aims to further strengthen its capabilities to develop, manufacture and commercialize next-generation bispecific antibodies and novel treatment combinationsBioNTech...
Nasdaq GlobeNewswire
13/11/2024

Global Dermatological Drugs Market to Cross USD 31 Billion by 2030 |…

Key Takeaways from the Dermatological Drugs Market Report Key Takeaways from the Dermatological Drugs Market Report To read more about the latest highlights related to the dermatological drugs market, get a snapshot of the key highlights entailed in the Global Dermatological Drugs Market Report Dermatological Drugs Overview Dermatological drugs are a category of medications used to treat a wide range of skin conditions, including acne, eczema, psoriasis, fungal infections, and dermatitis...
PR Newswire
13/11/2024

EAACI to Launch World Anaphylaxis Awareness Day on 21 November at FAAM-EUROBAT…

ATHENS, Greece, Nov.13, 2024(GLOBE NEWSWIRE) -- The European Academy of Allergy and Clinical Immunology (EAACI) is proud to announce the inaugural World Anaphylaxis Awareness Dayon 21 November 2024. This landmark initiative, held on the opening day of FAAM-EUROBAT 2024 in Athens, Greece, seeks to raise awareness and promote essential steps in preventing and managing anaphylaxis, a severe, potentially life-threatening allergic reaction.Anaphylaxis affects approximately 1-2% of...
Nasdaq GlobeNewswire
13/11/2024

Revolutionizing Heart Health: Frontier X Plus Gains FDA Clearance

"We have seen cardiac arrhythmias develop in individuals of all ages, and the incidence is significantly higher for individuals who are both active and have cardiac health risk factors. The percentage of population that falls in the confluence of these categories is continuously rising. Since the FX+ is able to capture ECGs during all kinds of motion and activity, we think this will be a game changer and significantly improve the early detection of cardiovascular disease," said…
PR Newswire
13/11/2024

Oculis to Present at the Stifel 2024 Healthcare Conference

Sylvia Cheung, Chief Financial Officer of Oculis, will participate in a fireside chat on November 18, 2024 at 3:35 pm ET. A live webcast of the fireside chat will be available here . The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Stifel representative to request meetings. A link to access the fireside chat, when available, will be posted to Oculis website on the Events & Presentation page under the Investors...
Nasdaq GlobeNewswire
13/11/2024

ImageBiopsy Lab launches IB Lab FROG: AI-powered Foot Measurements for…

IB Lab FROG addresses these challenges by covering the five most common use cases in foot assessment on dorsal-plantar and lateral X-ray images. Its automated measurements are based on radiological and orthopedic standards, significantly enhancing consistency, standardization, and precision in foot diagnostics. IB Lab FROG addresses these challenges by covering the five most common use cases in foot assessment on dorsal-plantar and lateral X-ray images. Its automated measurements are based on...
PR Newswire
13/11/2024

mediaire transforms radiology with AI, securing a European €12 million…

"Our AI solutions are not a futuristic dream. We have already created a reality that is helping doctors make better decisions and giving patients faster answers," says Dr. Andreas Lemke, CEO, and co-founder of mediaire. "We are seeing the impact on thousands of radiologists every day in hundreds of hospitals and radiology practices across Europe that are utilizing our AI solutions. With this investment, we will be able to scale these benefits to even more healthcare…
PR Newswire
13/11/2024

Royal Reception for KFSHRC Surgeons who performed the World 1st Full Robotic…

RIYADH, Saudi Arabia, Nov.13, 2024(GLOBE NEWSWIRE) -- His Royal Highness Crown Prince and Prime Minister Mohammed bin Salman received the Saudi medical team that performed the world's first fully robotic heart transplant at his office in Riyadh on Wednesday.The medical team from King Faisal Specialist Hospital & Research Centre (KFSHRC) of Riyadh had successfully performed the world's first heart transplant using a robot on a 16-year-old patient suffering from end-stage heart...
Nasdaq GlobeNewswire
13/11/2024
Altri  Comunicati